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Induced pluripotent stem (iPS) cells are derived from reprogrammed somatic cells and are similar to
embryonic stem (ES) cells in morphology, gene/protein expression, and pluripotency. In this study, we
explored the potential of iPS cells to differentiate into alveolar Type II (ATII)-like epithelial cells. Analysis
using quantitative real time polymerase chain reaction and immunoﬂuorescence staining showed that
pulmonary surfactant proteins commonly expressed by ATII cells such as surfactant protein A (SPA),
surfactant protein B (SPB), and surfactant protein C (SPC) were upregulated in the differentiated cells.
Microphilopodia characteristics and lamellar bodies were observed by transmission electron microscopy
and lipid deposits were veriﬁed by Nile Red and Periodic Acid Schiff staining. C3 complement protein, a
speciﬁc feature of ATII cells, was present at high levels in culture supernatants demonstrating
functionality of these cells in culture. These data show that the differentiated cells generated from iPS
cells using a culture method developed previously (Rippon et al., 2006) are ATII-like cells.
To further characterize these ATII-like cells, we tested whether they could undergo epithelial to
mesenchymal transition (EMT) by exposure to drugs that induce lung ﬁbrosis in mice, such as bleomycin,
and the combination of transforming growth factor beta1 (TGFb1) and epidermal growth factor (EGF).
When the ATII-like cells were exposed to either bleomycin or a TGFb1–EGF cocktail, they underwent
phenotypic changes including acquisition of a mesenchymal/ﬁbroblastic morphology, upregulation of
mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and
E-cadherin.
We have shown that ATII-like cells can be derived from skin ﬁbroblasts and that they respond to
ﬁbrotic stimuli. These cells provide a valuable tool for screening of agents that can potentially ameliorate
or prevent diseases involving lung ﬁbrosis.
& 2011 International Society of Differentiation. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
Epithelial to mesenchymal transition (EMT) is one of the processes
in the body responsible for organogenesis and cellular plasticity
giving rise to mesenchymal phenotypes such as ﬁbroblasts and
myoﬁbroblasts from other types of mature cells. This transformation
is characterized by loss of cell to cell contact marked by a decrease in
cell adhesion protein E-cadherin (Kalluri and Neilson, 2003; Rippon
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et al., 2006) and a switch to N-cadherin (Brabletz et al., 1998),
a change of morphology from a ﬂattened epithelial cell type into a
spindle-shaped, ﬁbroblast-like appearance, and subsequent acquisition of cytoskeletal markers (S100A4, a-Sma, Vim, b-Catenin ), extracellular matrix proteins (Col1, Col3, Fn1, Lama5), and transcription
factors (Snai1, Snai2, Zeb1, Twist1, Lef-1, Ets-1, Gsc) (Kalluri and
Neilson, 2003; Zeisberg and Neilson, 2009).
Several factors have been shown to induce EMT. Oncogenic
pathways such as Ras, Wnt/b-Catenin, and Notch can induce EMT
associated with repression of E-cadherin (Boyer et al., 1997).
Environmental factors such as hypoxia and oxidative stress also
contribute to the EMT phenotype (Manotham et al., 2004).
Activation of the canonical Smad signaling pathway via tandem
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effects of transforming growth factor beta1 (TGFb1) and epidermal
growth factor (EGF) have been shown to be major mediators of
EMT (Piek et al., 1999). Bleomycin, which acts by preventing
incorporation of thymidine into the DNA, promotes EMT by
inducing DNA strand breaks (Yamamoto et al., 2000). Serious
complications of EMT in tissues involve impaired normal organ
functions, and may eventually result in ﬁbrotic lung diseases.
Embryonic stem cells (ESCs) are ideal for studying cell differentiation because of their unlimited self renewal property and
pluripotency (Andrews, 2002; Bodnar et al., 2004; Ohtsuka and
Dalton, 2008). Various laboratories have shown that alveolar
epithelial cells can be derived from ESC in vitro (Coraux et al.,
2005; Rippon et al., 2008; Wang et al., 2007a) but the use of ESC
has major drawbacks such as immune rejection and ethical issues
due to the utilization of embryonic tissues. In 2006, a method for
retrodifferentiation of somatic cells to embryonic-like cells emerged
by introduction of deﬁned transcription factors (Takahashi and
Yamanaka, 2006). These cells have indistinguishable properties to
ESC such as morphology, gene expression proﬁle, and pluripotency.
Success in utilizing iPS cells in studying disease states has been
presented by various laboratories including our own (Alipio et al.,
2010; Hanna et al., 2007; Xu et al., 2009).
Here we demonstrate the ability to induce EMT in an in vitro
cell culture system of ATII-like cells derived from iPS cells. These
cells are useful tools in searching for new biomarkers of EMT or
novel drugs that can prevent EMT.

2.3. Epithelial to mesenchymal (EMT) induction of ATII cells
Stage 3, Day 7 ATII-like cells grown to 80% conﬂuency were
treated with bleomycin (APP Pharmaceuticals LLC, Schaumburg,
IL) at 1, 2, 4, 8, and 16 mg/ml ﬁnal concentration. Concurrently, the
combined effects of TGFb1 and EGF on the Stage 3, Day 7 ATII-like
cells were also assessed. We tested three doses of TGFb1 and EGF
(both from Millipore Billerica, MA): 5 ng/ml TGFb1 þ50 ng/ml EGF,
10 ng/ml TGFb1 þ100 ng/ml EGF, and 20 ng/ml TGFb1 þ 200 ng/ml
EGF. The cells were exposed to either of the ﬁbrosis-inducing
treatments for 2, 4, and 7 days. Culture conditions were repeated
at least three times in independent experiments.
2.4. Nile red
To assess lipid deposits, Stage 3 Day 7 ATII-like cells grown to
80% conﬂuency were stained with Nile Red (Sigma, St. Louis, MO)
according to the manufacturer’s instruction.
2.5. PAS staining
To determine the presence of glycolipids, Stage 3 Day 7 ATIIlike cells grown to 80% conﬂuency were stained with Periodic
Acid Schiff staining (EMD Chemicals Inc, Gibbstown, NJ) according
to manufacturer’s instruction.
2.6. Polymerase chain reaction (PCR)

2. Materials and methods
2.1. Generation of induced pluripotent stem (iPS) cells from murine
tail-tip ﬁbroblasts
Normal ﬁbroblasts from the tail-tip of green ﬂuorescent
protein (GFP) transgenic mice [(C57BL/6-Tg(UBC-GFP) 30Scha/J
Stock#004356, Jackson Laboratory, Bar Harbor, ME)] were transduced with four retroviruses encoding transcription factors Oct4,
Sox2, Klf4, and C-Myc (purchased from Stemgent, San Diego, CA)
and iPS cells were produced and characterized as previously
described (Alipio et al., 2010; Okita et al., 2007; Takahashi and
Yamanaka, 2006; Wernig et al., 2007). Fourteen to twenty days
post transduction, 10 iPS subclone colonies were picked and
expanded. Two representative clones with similar morphology
and intensity of GFP expression were used for alveolar Type II
(ATII) epithelial cell differentiation. These clones exhibited all the
characteristics of typical iPS cells: expression of transducing
transcription factor mRNA as well as additional embryonic stem
cell markers and the ability to form teratomas when injected
subcutaneously into the ﬂanks of nude mice, properties that we
and others have reported previously (Alipio et al., 2010; Okita
et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007).
2.2. In vitro differentiation of iPS cells into alveolar Type II (ATII-like)
epithelial cells
Alveolar Type II (ATII-like) cells were derived from iPS cells by a
three-stage differentiation process, following previously described
methods for murine ES cells with slight modiﬁcations (Rippon et al.,
2006). The modiﬁcations include the following: (1) enhanced attachment of Embryoid Bodies (EBs) at Stage 2 by culture of EBs in media
containing FBS instead of Knock Out Replacement Serum (KOSR),
(2) improved viability of ATII-like epithelial cells by passaging the
differentiating cells at Stage 2 Day 5 of alveolar cell differentiation
instead of continuous culture for 11 days during the Stage 2 process,
and (3) improved viability of ATII-like epithelial cells by supplementing the small airway growth medium with 10% FBS in Stage 3.

Total RNA was isolated using the Trizol reagent (Invitrogen,
Carlsbad, CA) and 2 mg of total RNA was reverse transcribed using
cDNA Archive kit (Applied Biosystems, Foster City, CA). PCR
reactions were ran using Platinum PCR Supermix High Fidelity
(Invitrogen) and quantitative real time PCR was performed using
the Power SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA). Data was acquired using 7500 FAST Real Time
PCR system (Applied Biosystems, Foster City, CA) and analyzed
using Comparative CT method via SDS FAST System software
version 1.4.0. Primer sequences for endogenous/total retroviral
transcripts (Boyer et al., 1997; Kalluri and Neilson, 2003), the lung
markers (Rippon et al., 2006), and other gene speciﬁc oligonucleotides (obtained from Roche’s UniversalProbe library) are
reported in the Supplementary Table S1.
2.7. Immunoﬂuorescence staining
Immunoﬂuorescence staining was performed on actively dividing cells cultured in 12 well plates as previously described (Alipio
et al., 2010; Hanna et al., 2007; Xu et al., 2009). Primary antibodies
diluted at 1:100 in 1% BSA were used for immunoﬂuorescence
staining: Oct4 and SSEA-1 (Chemicon, Billerica, MA), Sox2, Nanog,
SPA, SPB, SPC, ABCA3, CC10, Cytochrome P450 A1A (all from Santa
Cruz Biotechnology, Santa Cruz, CA), and Aquaporin 5 (Abcam,
Cambridge, MA). The secondary antibodies used were goat antimouse PE (Sigma, St Louis, MO), goat anti-rabbit-PE and rabbit
anti-goat-PE (both from Southern Biotech, Birmingham, Alabama).
Nuclei were counterstained with 1 mg/ml 40 ,6-diamidino-2-phenylindole (Sigma, St Louis, MO) for 10 min. Images were captured
by QImaging camera (QImaging, Surrey, BC) and analyzed by
QimagingPro software (QImaging, Surrey, BC).
2.8. Transmission electron microscopy (TEM)
One 100 mm semi-conﬂuent tissue culture dish containing
Stage 3 Day 7 ATII-like epithelial cells was trypsinized, the cells
were washed with serum free medium containing 0.5% bovine
serum albumin and centrifuged for 5 min at 300g. The cell pellet
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was ﬁxed with EM-grade 1X Karnovsky Fixative solution containing 2% Paraformaldehyde, 2.5% Glutaraldehyde and 0.1 M Sodium
Phosphate Buffer (Electron Microscopy Sciences, Hatﬁeld, PA) for
15 min. The cells were centrifuged, fresh ﬁxative solution was
added to the cell pellet, and the samples were packaged in
between ice packs to be shipped to University of North Texas
for further sample preparation. Once received, the ﬁxed sample
was washed three times with fresh 0.1 M sodium phosphate
buffer. The samples were centrifuged and the cells were ﬁxed
with a second ﬁxative solution of 2% OsO4 (Electron Microscopy
Sciences, Hatﬁeld, PA) in water for 1 h at room temperature. The
sample was washed again three times as previously described and
dehydrated in a series of different ethanol concentrations. To ease
inﬁltration of Epon into the cell pellet, the sample was treated
with propylene oxide (Sigma, St. Louis, MO) two times for 15 min.
The sample was then inﬁltrated at 1:1 with propylene oxide/Epon
for 30 min, then at 1:3 ethanol/propylene oxide for 30 min, and
ﬁnally at 100% Epon overnight. The following day, the sample was
exposed to fresh Epon for 2 h before it was placed into a 70 1C
oven for 18–24 h to polymerize the plastic. 70–100 nm thick
sections were contrast stained with a saturated uranyl acetate
solution (Sigma, St. Louis, MO) in 70% ethanol for 10 min, washed
with deionized water, stained with Satos’ lead citrate solution
(Sigma, St. Louis, MO) for 1 min, washed with deionized water,
and air dried. The stained sections were viewed on a Zeiss EM 910
TEM with 100 kV voltage. Images were captured on Kodak ﬁlm
SO-163, developed and scanned on a ﬂatbed scanner to convert
them into electronic ﬁles.
2.9. Western blot
Protein from Stage 3 Day 7 ATII-like cells (with and without
EMT inducers) in 100 mm culture dish was quantiﬁed using EZQs
Protein Quantitation Kit (Invitrogen, Carlsbad, CA) in triplicate
using an ovalbumin standard curve. Western blot analysis was
performed as described (Wang et al., 2007b; Wishart et al., 2007).
30 mg of protein from each sample was loaded into NuPAGEs
4–12% Bis–Tris Gel (Invitrogen, Carlsbad, CA). The primary antibodies used were SPC, a-Sma, E-Cadherin (Santa Cruz Biotechnology, Santa Cruz, CA), and b-Actin (LI-COR, Lincoln, NE), each at a
1:50 dilution. Secondary antibody dilution was 1:10,000 for
donkey anti-goat IRDye 800CW, goat anti-rabbit IRDye 800CW,
and goat anti-mouse IRDye 800CW (all from LI-COR, Lincoln, NE).
Protein detection was performed using Odyssey Infrared Imaging
System (LI-COR, Lincoln, NE).
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3.1. Differentiation of iPS cells into alveolar Type II (ATII-like)
epithelial cells
The three-stage protocol for the direct differentiation of iPS
cells into ATII-like cells (see Section 2) generated ﬂattened
epithelial-like morphology (Fig. 1a) at Stage 3 Day 7. Electron
microscopic analysis at this stage showed multiple lamellar
bodies and microphilopodia, characteristics indicative of an ATII
cell differentiation (Fig. 1b). mRNA expression of lung speciﬁc
markers such as surfactant protein A (SPA), surfactant protein B
(SPB), surfactant protein C (SPC, a Type II alveolar cell speciﬁc
marker), and surfactant protein D (SPD), were upregulated at
various time points during the ﬁnal stage of the differentiation
(Fig. 1c). There was an approximately 2.5 fold increase of SPC
expression at Stage 3 Day 6 ATII-like cells compared to the
ﬁbroblast control, and the expression further increased at Stage
3 Day 16 ATII-like cells, suggesting that the cells persisted long
term in this culture condition. This information is helpful for cell
therapy studies involving lung progenitor transplantation for
regenerative and injury repair. Clara cells (marked by CC10 gene)
were also present and were upregulated at Stage 3 Day 6 but were
markedly depleted by Stage 3 Day 16 differentiation, suggesting selective differentiation or accumulation of ATII-like cells
(Fig. 1c). Protein expression analysis by immunoﬂuorescence
staining of Stage 3 Day 7 ATII-like cells showed positive staining
for ABCA3 (marker for gene present in the lamellar bodies and
involved in regulation of lipid transport and membrane trafﬁcking), CC10 (marker for Clara cell), cytochrome P450 A1A (marker
for alveolar epithelium), SPA (a pulmonary surfactant protein
marker), SPB (a pulmonary surfactant protein marker), SPC
(marker for ATII, a pulmonary surfactant protein marker), and
Aquaporin 5 (marker for the major water channel expressed in
Alveolar Type I cells in the lung) at Stage 3 Day 7 (Fig. 2a).
Intracellular lipid deposits were detected in these cells by Nile
Red ﬂuorescence staining (Fig. 2b) and Periodic Acid Schiff (PAS)
staining (Fig. 2c). MLE-12, a murine lung epithelial cell line, was
used as the positive control for both lipid tests. ATII-like cells
were also able to synthesize and secrete murine complement
factor 3, which was detected at high levels relative to ﬁbroblast
control by ELISA, indicating successful generation of murine
ATII-like cells that can provide pulmonary host defense and are
able to produce an acute phase protein (Fig. 2d).
By morphology, transmission electron microscopy, gene
expression, intracellular protein expression, Nile red and PAS
staining, and the secretion of C3 strongly suggests that ATII-like
cells have been generated in vitro.

2.10. Mouse C3 ELISA
The supernatant from Stage 3 Day 7 ATII-like cells was
collected and tested for the presence of C3 protein. The quantiﬁcation of Complement factor 3 (C3) was performed using a
highly sensitive immunoassay Mouse C3 ELISA (Immunology
Consultants Laboratory, Inc. Newberg, OR) according to manufacturer’s instructions.

3. Results
Skin ﬁbroblasts from GFP-C57BL6 mice were retrodifferentiated to iPS cells as previously described (Takahashi and
Yamanaka, 2006), followed by a programmed induction of iPS
cells to differentiate into alveolar Type II epithelial cells as
previously described (Rippon et al., 2006) with minor modiﬁcations (see Section 2). Finally, the ATII-like cells were treated with
ﬁbrotic stimuli such as bleomycin or TGFb1–EGF to create a
ﬁbrotic model in vitro.

3.2. ATII-like epithelial cells undergo epithelial to mesenchymal
transition (EMT) by exposure to bleomycin
We initially determined the condition for the ATII-like cells to
undergo EMT by titrating the bleomycin from 1 to 16 mg/ml and
exposing the cells for 2, 4, and 7 days (data not shown). Induction
of EMT was assessed by morphology, protein expression of SPC,
Col1, and a-Sma, by quantitative real time PCR analysis (lung
markers and EMT-related genes), and western blot (E-cadherin
and a-Sma).
ATII-like cells responded to the treatment in a time and dose
dependent manner. Because the cells carry the GFP gene, ﬂuorescence images gave the best representation of the morphological
changes. Two days of drug treatment gave only slight changes in
morphology at the highest doses (8 and 16 mg/ml) while the
untreated control maintained an epithelial phenotype. qRT-PCR
analysis also showed very minimal upregulation of EMT markers
with similar expression to the untreated control (data not shown).
After 4 days of treatment, morphological evidence of EMT is observed
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Fig. 1. (a) Morphology of the cells at each stage of the 3-step differentiation protocol (see Section 2). At Stage 1, iPS cells were differentiated into embryoid bodies (EBs), at
Stage 2, EBs were attached to the tissue culture dish, and at Stage 3, a ﬂattened epithelial-like cell phenotype was the prominent population grown in ATII selective media.
(b) Transmission electron microscopy analysis of Stage 3 Day 7 cells showing microphilopodia (cytoplasmic extensions) and lamellar bodies (red arrows) typically seen in
murine ATII cells. (c) Gene Expression of ATII markers (SPA, SPB, SPC, SPD) and Clara cells (CC10). All the ATII markers were upregulated at Stage 3 Day 6 and Day 16 of the
differentiation while the Clara cell marker was only detected at the earlier time point indicating selected ATII differentiation/accumulation at the ﬁnal stage. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)

with cells adopting a ﬁbroblast-like cell shape with extensive loss of
cell to cell contact. This was observed in cells treated with 4 mg/ml of
bleomycin treatment, and became more pronounced as the dose
increased (Fig. 3a). Key EMT markers such as Snai1, Snai2 (Slug), Gsc,
Cdh2, Col1, Mmp3, and Mmp9 were upregulated by qRT-PCR. Loss of
E-cadherin, a hallmark of EMT, is also observed (Fig. 3b). With 7 days
of treatment, a more extensive morphology change is observed even
at a dose of 1 mg/ml bleomycin, (data not shown). More EMT markers
were acquired at this dose and exposure time.
We then assessed the surfactant protein C (SPC) mRNA
expression of the ATII-like cells after bleomycin treatment for 2,
4, and 7 days and showed that after 4 days of treatment, SPC is
markedly downregulated by approximately 80% compared to the
untreated control (Fig. 3b) starting at 2 mg/ml bleomycin. SPC
protein expression was also analyzed at these time points by
immunostaining (Fig. 3c) and showed SPC protein depletion as
the dose of the bleomycin treatment increases in treated cells
while high expression of SPC is observed in untreated control.
E-cadherin is usually expressed very highly in ATII epithelial cells,
and in this study, qRT-PCR (Fig. 3b) and western blot (Fig. 3d)
analyses show that E-cadherin expression is also depleted as the
concentration of the bleomycin treatment increases.

To further document that EMT is occurring in ATII-like cells,
we analyzed gene expression of 52 EMT-related markers that
were shown to be signiﬁcantly upregulated during EMT by
qRT-PCR (Kalluri and Neilson, 2003; Zeisberg and Neilson, 2009).
We analyzed samples collected after 2, 4, and 7 days of bleomycin
treatment at various doses. After 2 days of treatment, several
EMT-related genes are upregulated relative to the untreated
control group. The number of acquired markers continued to
increase after 4 and 7 days of treatment, increasing from 13.5% to
36.5% positive hits (day 4) and 13.5% to 73.1% (day 7) in cells
treated with 8 mg/ml bleomycin.
Many genes are related to EMT and its progression to transdifferentiation, including the switching of E-cadherin to N-cadherin.
Although the E-cadherin to N-cadherin switch was not observed
after 2 days, only marginally indicated at any bleomycin dose
after 4 days of treatment, the switch was exhibited at all
bleomycin doses after 7 days of treatment. Indeed E-cadherin
expression was barely detectable after 7 days of treatment at all
doses tested.
Upregulation of integrins are also linked to EMT since EMT
disturbs the cell to ﬁbrillar extracellular matrix interaction. The
integrin 5 (integrin alpha 5, a ﬁbronectin receptor) and Itgav
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Fig. 2. (a) Protein expression analysis by immunoﬂuorescence staining of Stage 3 Day 7 ATII-like cells showing positive staining for ABCA3 (a lamellar body marker), CC10
(a Clara cell marker), cytochrome P450 A1A, SPA, SPB, SPC (all alveolar markers), and aquaporin 5 (an AT Type I marker). All images were taken at 100  magniﬁcation. (b) Nile Red
staining showing lamellar bodies (cytoplasmic white ﬂuorescence dots) in Stage 3 Day 7 ATII-like epithelial cells. The MLE epithelial cell line was used as positive control. Images
were taken at 200  magniﬁcation. (c) PAS staining showing positivity for the presence of lipid (red stain) in Stage 3 Day 7 ATII-like epithelial cells. MLE murine epithelial cell line
was used as control. Images were taken at 200  magniﬁcation. (d) Complement Factor 3 (C3) protein quantiﬁcation in the supernatant of Stage 3 Day 6 and Day 16 ATII-like cells
by an ELISA assay. Very high levels of C3 protein are secreted by the differentiated cells. Murine serum was used as the positive control and culture media from the ﬁbroblasts was
used as the negative control. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 2. (continued)

(integrin alpha V), both were highly expressed after 7 days of
bleomycin treatment 8 mg/ml. This data suggests that the cells are
potentially motile and can invade ECM from the basal membrane.
Additionally, E-cadherin is directly inﬂuenced by the expression of Snai1 transcription factor, a master gene relating to EMT.
During EMT progression, Snai1 suppresses E-cadherin gene
expression. Upregulation of Snai1 and downregulation of E-cadherin
was ﬁrst observed in cells treated for 4 days: at higher doses of
bleomycin cellular toxicity was observed and quantiﬁcation of
these protein expression levels was deemed unreliable. The
expression of S100A4, a ﬁbroblastic EMT marker seen in ﬁbrotic
diseases and cancer (Chen et al., 2001), is usually correlated with
a-Sma gene expression levels. After 7 days of bleomycin treatment S100A4 was highly expressed although no upregulation was
observed after 2 or 4 days of treatment. In contrast, a-Sma was
upregulated early at Day 2, with 4 and 8 mg/ml bleomycin, with

expression approximately 3 fold more than the untreated control.
After 7 days of treatment, the a-Sma expression level was
still elevated approximately three fold. Therefore, the co-expression of S100A4 and a-Sma after 7 days of 8 mg/ml bleomycin
exposure generated EMT-derived ﬁbroblasts. Additionally, Collagen1, an ECM protein that is directly correlated with EMT
(Yamamoto et al., 2000), was highly upregulated after 4 days of
treatment at all doses of bleomycin by immunostaining (Fig. 3f)
and quantitative real time PCR analysis (Fig. 3g). No cellular
toxicities were observed after 2 days of treatment; however,
slight toxicity was observed at the highest bleomycin dose
on Days 4 and 7 of treatment as measured by PI staining (data
not shown).
The collective data indicates that bleomycin exposure at 8 mg/ml
for 7 days induces the ATII cells to exhibit plasticity, transdifferentiate into a different cell type and undergo EMT.
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3.3. Induction of EMT by TGFb1 and EGF
Various laboratories have shown that TGFb1 induces EMT in
many organ systems including the lungs (Gal et al., 2008; Illman
et al., 2006; Wang et al., 2008). It has also been shown that EGF
enhances EMT when coupled with TGFb1 (Uttamsingh et al.,
2008). In this study, we investigate the combined effects of TGFb1
and EGF on inducing EMT in ATII-like derived from iPS cells.
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EMT induction was achieved by treating Stage 3 Day 7 ATII-like
cells with the following TGFb1–EGF concentrations: 5 ng/ml
TGFb1 þ 50 ng/ml EGF, 10 ng/ml TGFb1 þ100 ng/ml EGF, and
20 ng/ml TGFb1 þ200 ng/ml EGF, for 2, 4, and 7 days. The progression
of EMT was assessed using the same tests as applied to EMT induced
by bleomycin.
Morphological changes were already obvious after 2 days of
treatment (Fig. 4a). The cells had ﬂattened and elongated spindle-

Fig. 3. (a) Morphology of Stage 3 Day 7 cells after four (4) days of bleomycin treatment. ((A) non-treated, (B) treated with 1 mg/ml bleomycin, (C) treated with 2 mg/ml
bleomycin, (D) treated with 4 mg/ml bleomycin, (E) treated with 8 mg/ml bleomycin, (F) treated with 16 mg/ml bleomycin.) EMT-like phenotypic changes were observed as
the bleomycin dose increased. Images were taken at 100  magniﬁcation. (b) Quantitative real time PCR (qRT-PCR) analysis of Stage 3 Day 7 ATII-like cells after four
(4) days of bleomycin treatment showing mRNA expression of SPC and E-cadherin decreases while a-Sma gene expression increases as bleomycin dose increases.
(c) Surfactant protein C expression of Stage 3 Day 7 ATII cells after four (4) days of bleomycin treatment showing decreasing SPC protein expression as the bleomycin dose
increases ((A) non treated (100  ), (B) treated with 1 mg/ml bleomycin (100  ), (C) treated with 4 mg/ml bleomycin (200  ), (D) treated with 16 mg/ml bleomycin (200  )).
(d) Western blot analysis of Stage 3 Day 7 ATII-like cells after four (4) days of bleomycin treatment using E-cadherin and a-Sma. Protein expression of E-cadherin (a cell
adhesion marker) decreases as bleomycin dose increases while myoﬁbroblasts marker, a-Sma, increases indicating induction of ATII-like cells to EMT. (e) The EMT inducing
condition using bleomycin is achieved by treatment of 8 mg/ml bleomycin exposed for seven days (7) on Stage 3 Day 7 ATII cells. Gene expression of EMT markers was
quantiﬁed by quantitative real time PCR analysis. (f) Immunoﬂuorescence staining of Col1 (an extracellular matrix usually upregulated in EMT) on Stage 3 Day 7 ATII-like
cells after 4 days of treatment showing marked increase in protein expression as the bleomycin dose increases ((A) non-treated (100  ), (B) treated with 2 mg/ml
bleomycin (100  ), (C) treated with 4 mg/ml bleomycin (100  ), (D) treated with 8 mg/ml bleomycin (200  )). (g) Upregulation of Collagen 1 quantiﬁed by qRT-PCR on
Stage 3 Day 7 ATII-like cells after 4 days of treatment.

96

Z.A. Alipio et al. / Differentiation 82 (2011) 89–98

Fig. 3. (continued)

shaped features at 5 ng/ml TGFb1 þ50 ng/ml EGF that became
more pronounced as the dose increases. qRT-PCR analysis was
performed and approximately 44% of the EMT markers, tested
such as extracellular matrix markers (Col3, Col5, Ctnnb1, Gsc,
Smad2, Snai1, Snai2 (Slug), and Twist1) and differentiation/
development markers (Col1, Cdh2, Itga5, Itgav, Mmp2, Mmp3,
Mmp9, and Timp1) were upregulated after only 2 days of
treatment. Downregulation of E-cadherin also was already noted
at this early stage of transdifferentiation by qRT-PCR analysis

(Fig. 4e). More EMT markers were upregulated as the concentration
of the growth factor cocktail increases for example, protein expression of SPC, Col1, and a-Sma was readily observed by immunoﬂuorescence staining. SPC was highly expressed prior to treatment
and slowly lost expression as the concentration of TGFb1–EGF
increases (Fig. 4c). Col1 protein expression is minimally expressed
prior to exposure and increased its expression as the dose of TGFb1–
EGF increases (Fig. 4c). a-Sma expression was not profound by
immunoﬂuorecence staining (Fig. 4c) but showed 2 fold increase of
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Fig. 4. (a) Morphology at Stage 3 Day 7 after two (2) days of TGFb1–EGF treatment starting at day 5 ((A) non-treated (100  ), (B) treated with 5 ng/ml TGFb1 þ 50 ng/ml EGF
(200  ), (C) treated with 10 ng/ml TGFb1 þ 100 ng/ml EGF (200  ), (D) treated with 20 ng/ml TGFb1 þ200 ng/ml EGF (200  ). At Day 2 of exposure, the effects of TGFb1–EGF
exposure on the ATII cells are robust. (b) Protein expression analysis by immunoﬂuorescence staining at Stage 3 Day 7 ATII cells treated with TGFb1–EGF for 2 days. SPC
expression slowly decreases while Col1 increases as the dose of TGFb1–EGF treatment increases. Images were taken at 100  magniﬁcation. (c) Western blot analysis of
Stage 3 Day 7 ATII-like cells after four (4) days of TGFb1–EGF treatment showing decreasing SPC and E-cadherin protein expression while the expression of a-Sma increases.
(d) Quantitative real time PCR analysis of Stage 3 Day 7 ATII-like cells TGFb1–EGF treatment showing mRNA expression of Surfactant Protein C (SPC), a-Sma and E-cadherin.
(e) The EMT inducing condition using TGFb1–EGF is achieved by treatment of 10 ng/ml TGFb1 þ 100 ng/ml EGF exposed for four days (4) on Stage 3 Day 7 ATII cells. Gene
expression of EMT markers was quantiﬁed by quantitative real time PCR analysis.

mRNA expression at 10 ng/ml TGFb1 þ100 ng/ml EGF by qRT-PCR
analysis (Fig. 4d). After 4 days of exposure, the cells have transformed robustly into a mesenchymal/ﬁbroblastic phenotype feature
(data not shown) and the qRT-PCR analysis shows that multiple
EMT markers are highly upregulated (Fig. 4e). a-Sma is minimally
expressed throughout by immunoﬂuorecence staining (Fig. 4b) but
is highly expressed in western blot analysis (Fig. 4c). E-cadherin was
downregulated at all doses at this time point. Samples were
obtained from Days 2, 4, and 7 of exposure at all doses and analyzed
by qRT-PCR for EMT markers. SPC and E-cadherin were downregulated while a-Sma was upregulated as the dose increases. Other
features of EMT such as cadherin switch, upregulation of integrin
markers, S100A4, a-Sma and Col1 were also observed at all doses as
early as Day 2 of TGFb1–EGF exposure.
In summary, induction of EMT in ATII-like cells can be
achieved after 2 days of exposure at either of the growth factor
doses tested with a slight preference to 20 ng/ml TGFb1 þ200 ng/ml
EGF dose due to morphology feature alterations (loss of cell to cell
contact and ﬁbroblastic morphology), qRT-PCR results and protein
expression analysis although optimal condition to induce EMT is
Day 4 of treatment with the 10 ng/ml TGFb1 þ100 ng/ml EGF dose.

Prolonged exposure to TGFb1–EGF cocktail (any dose at Day 7) is not
a recommended culture condition due to poor cell morphology and
increased presence of apoptotic cells.

4. Discussion
iPS cells have been recently used extensively as a cell source
for differentiation into many discreet cell types of the body and to
study their potential role in cellular therapy or to investigative
the molecular basis of diseases (Alipio et al., 2010; Hanna et al.,
2007; Xu et al., 2009). We document here that iPS cells can be
used to generate ATII-like epithelial cells in vitro and that they
undergo EMT when treated with the use of ﬁbrosis stimulating
agents such as bleomycin and TGFb1–EGF. These observations
suggest that the ATII-like cells can be used as an in vitro model to
study pathophysiology of diseases involving ﬁbrosis.
These ATII-like cells have the characteristics and features of
ATII epithelial cells similar to the murine lung epithelial cell line
MLE-12. The ATII-like cells have an epithelial phenotype with
microphilopidia extensions, they express surfactant proteins, and
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test positive for the presence of lamellar bodies and lipid deposits.
The ATII-like cells mature slowly in culture and they retain their
ATII-like features for a prolong period of time.
We evaluated the potential of ATII-like cells to be used as a
model of lung ﬁbrosis in vitro by treating them with ﬁbrosis
stimulation agents such as bleomycin and TGFb1–EGF. Both
bleomycin and TGFb1–EGF readily induce EMT; however, the
response times and the resulting phenotypic changes were not
identical. ATII-like cells treated with bleomycin acquired a
mesenchymal phenotype and express various proteins relating
to EMT more slowly than growth factor treated cells, acquiring
the most EMT features only after 7 days of exposure and at a
concentration of 8 mg/ml bleomycin. E-cadherin, normally highly
expressed in ATII cells, was signiﬁcantly depleted only at high
bleomycin dose and prolonged exposure time. Surfactant protein
C, another speciﬁc marker for ATII cells, was signiﬁcantly downregulated. Concurrenty, bleomycin treated cells acquired several
important EMT markers such as Col1, Snai1, Snai2, Vim, a-Sma,
S100A4, and Twist1, further evidence that the ATII-like cells have
indeed transformed into mesenchymal cells.
TGFb1 is involved in many physiological functions in the body
such as tissue development and differentiation, extracellular matrix
production and apoptosis. This protein also has been implicated as
the root cause of EMT during injury, especially in the lungs. It is
endogenously expressed in injured tissues as well as in patients
suffering from ﬁbrotic diseases such as idiopathic pulmonary
ﬁbrosis (IPF) and is a major EMT inducer (Illman et al., 2006;
Uttamsingh et al., 2008; Wang et al., 2008). For TGFb1–EGF treated
cells in vitro, transdifferentiation occurred within the ﬁrst two days
in the treatment process, even at the lowest dose of the cocktail
used (5 ng/ml TGFb1 þ50 ng/ml EGF). Full expression of EMT-related
protein was observed by 4 days of treatment suggesting an
involvement of a more robust signaling pathway (more likely a
Smad dependent pathway due to enhanced Smad expression) and is
consistent with observations from many laboratories using this
ﬁbrosis stimulating agent. The number of acquired EMT markers
doubled compared to the ATII treated with bleomycin. Markers of
differentiation and development (Col3, Col5, Ctnnb1, Jag1, Notch,
Smad2, Tgfb3, Tmeff1, Twist1 and Vcan), cytoskeleton (Vim) and
extracellular matrix (Cdh2, Col1, Itga5, Itgav, Mmp2, and Mmp9)
were all enhanced in TGFb1–EGF treated cells.
The data presented here strongly indicate that the ATII-like cells
produced from skin ﬁbroblast via an iPS cell intermediate can be
utilized to study the molecular mechanism of EMT in lung cells
in vitro. The study of the intracellular signaling pathways involved in
both bleomycin-mediated or TGFb1–EGF-mediated EMT will need to
be examined and will hopefully lead to therapeutic targets for the
amelioration of ﬁbrosis in the lungs and other organs.
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